Status:
COMPLETED
Plasma Determination of Glucagon-like Peptide 2 as a Predictor of Recovery in Adults With Acute Intestinal Failure
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
Centre for Ocular Research & Education, Canada
St Mark's Hospital Foundation
Conditions:
Short Bowel Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to investigate the theory that the plasma level of Glucagon like peptide 2 (GLP-2) in patients with intestinal failure can predict their clinical recovery.
Detailed Description
When major segments of small bowel have been removed surgically, or damaged by disease, the length of the residual bowel may be inadequate to maintain overall nutrition and the net result is described...
Eligibility Criteria
Inclusion
- Men and woman, aged 18 years of age or older at the time of signing the informed consent form.
- Referral to or direct admission to St. Mark's Hospital.
- Acute intestinal failure resulting in TPN dependency as a result of major intestinal resection performed during admission to St. Mark's or at the referring hospital.
Exclusion
- Inability to give consent or comply with the study.
- Inability to take test meal (unable to be tested)
- Severe renal impairment (interference with GLP-2 excretion)
- Severe uncorrected anaemia (preventing additional blood-letting)
- Uncontrolled diabetes mellitus (risk of hyperglycaemia)
Key Trial Info
Start Date :
February 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00180648
Start Date
February 1 2005
End Date
February 1 2008
Last Update
February 22 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.